Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis (CELEB)

August 26, 2019 updated by: Marilyn Glassberg

A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell (hMSC) Infusion in Patients With Non-Cystic Fibrosis Bronchiectasis

To demonstrate the safety of bone marrow-derived allogeneic human Mesenchymal Stem Cells (hMSCs) in patients with bronchiectasis receiving standard of care therapy, and to explore treatment efficacy

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A Phase 1 investigation will be performed to test the safety of two doses of bone-marrow derived hMSCs (20,000,000 and 100,000,000) administered via peripheral intravenous infusion.

Group 1: 3 subjects will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion Group 2: 3 subjects will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion Interim safety analysis will be performed four weeks after the 1st subject is enrolled in each cohort. Continued safety and tolerability with review of adverse events (AEs) will be assessed at each visit. Efficacy parameters (pulmonary function tests, lung diffusion capacity, lung volumes, 6-Minute Walk Test (6MWT), and dyspnea/Quality of Life (QOL) questionnaires) will be assessed every 12 weeks until study completion. Clinical laboratory tests to assess safety will be performed at every visit.

High Resolution Computed Tomography (HRCT) scan will be performed at the baseline visit (if not done within three months prior to enrollment) and then at week 24.

Study Type

Interventional

Enrollment (Actual)

6

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Florida
      • Miami, Florida, United States, 33136
        • University of Miami Hospitals & Clinics

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 87 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Provide written informed consent,
  • be between 30 and 87 years old at the time of signing the Informed Consent,
  • weight over 45 and under 150 kg,
  • have a clinical diagnosis of non-CF bronchiectasis prior to screening,
  • Have had at least 2 exacerbations in the past year as documented by physician office or hospital visits (Use of antibiotics of at least one time in the last year),
  • Show a baseline FEV1 between 25% and 85% predicted and over or equal to 1 L and a baseline diffusion capacity of lung for carbon monoxide (DLCO) over or equal to 30% (corrected for hemoglobin but not alveolar volume),
  • Have a normal Right Ventricular function, as documented by Doppler echo or right heart catheterization,
  • if a female of childbearing potential, agree to abide by contraception rules defined below.
  • Subjects may receive nondrug therapies including oxygen supplementation not greater than 4 Liters per minute and pulmonary rehabilitation.
  • Subjects may be on chronic macrolide or inhaled antibiotic treatment bronchiectasis

Exclusion Criteria:

  • Have HRCT and or surgical lung biopsy results inconsistent with the diagnosis of non-CF bronchiectasis. (Exclusion of emphysema and or diffuse parenchymal disease)
  • be unable to perform any of the assessments required for endpoint analysis (report safety or tolerability concerns, perform Pulmonary Function Tests (PFT) or HRCT, undergo blood draws, read and respond to questionnaire
  • If a female of childbearing potential, have a follicle stimulating hormone (FSH) under 25.8 IU/L
  • be actively treated for an acute infectious exacerbation of bronchiectasis
  • Have an active infection that is not treated
  • Have had active infections occurring within a minimum of 4 weeks of study treatment
  • Be currently on treatment for NTM infections
  • Have had positive sputum cultures for nontuberculous mycobacterial (NTM) within the past 6 months
  • Have a history of drug or alcohol abuse within the past 24 months.
  • Be currently receiving (or have received within four weeks of screening) experimental agents for the treatment of bronchiectasis or have been enrolled in clinical trials within the previous 30 days
  • Be actively listed (or expect future listing) for transplant of any organ.
  • Have clinically important abnormal screening laboratory values.
  • Have a serious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study.
  • Have any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study.
  • Have known allergies to penicillin or streptomycin.
  • Be an organ transplant recipient.
  • Have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma of skin, squamous cell carcinoma of skin, or cervical carcinoma.
  • Have a non-pulmonary condition that limits lifespan to less than 1 year.
  • Be serum positive for HIV, hepatitis BsAg (surface agent reactive) or Viremic hepatitis C.
  • Have hypersensitivity to dimethyl sulfoxide (DMSO)
  • Be unable to maintain saturated oxygen (SpO2) of more than 93% on room air at sea level at rest) or an SpO2 of more than 88% on room air over 5,000 feet (1524 meters) above sea level at rest.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group 1
3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
Biological: hMSCs
intravenous infusion of bone marrow-derived allogeneic stem cells
Other Names:
  • allogeneic mesenchymal stem cell
Experimental: Group 2
3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
Biological: hMSCs
intravenous infusion of bone marrow-derived allogeneic stem cells
Other Names:
  • allogeneic mesenchymal stem cell

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participant with treatment emergent serious adverse events
Time Frame: Week 4 post infusion
incidence of any treatment-emergent serious adverse events defined as the composite of death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities
Week 4 post infusion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in Colony Forming Units (CFUs) in semiquantitative culture of sputum
Time Frame: Participants will be followed from 1 week to an expected average of 24 weeks following infusion.
Difference in CFUs in semiquantitative culture of sputum
Participants will be followed from 1 week to an expected average of 24 weeks following infusion.
rate of decline of lung function
Time Frame: Participants will be followed from 12 weeks to an expected average of 24 weeks following infusion.
difference in absolute decline of forced expiratory volume at one second (FEV1) percent predicted
Participants will be followed from 12 weeks to an expected average of 24 weeks following infusion.
frequency of acute exacerbations
Time Frame: Participants will be followed from 12 weeks to an expected average of 48 weeks following infusion.
increased cough and sputum production, fever, new or worsened dyspnea in less than 30 days, new or worsened hypoxemia in the absence of other identifiable causes
Participants will be followed from 12 weeks to an expected average of 48 weeks following infusion.
reported dyspnea and quality of life assessment
Time Frame: Participants will be followed from 4 weeks to an expected average of 48 weeks following infusion.
using quality of life tool questionnaire QOL-B version 2
Participants will be followed from 4 weeks to an expected average of 48 weeks following infusion.
death from any cause
Time Frame: Participants will be followed for the duration of the trial, which is an expected average of 48 weeks.
death from any cause
Participants will be followed for the duration of the trial, which is an expected average of 48 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Marilyn Glassberg

Investigators

  • Principal Investigator: Glassberg K Marilyn, MD, University of Miami

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 4, 2016

Primary Completion (Actual)

May 15, 2019

Study Completion (Actual)

May 15, 2019

Study Registration Dates

First Submitted

December 4, 2015

First Submitted That Met QC Criteria

December 4, 2015

First Posted (Estimate)

December 9, 2015

Study Record Updates

Last Update Posted (Actual)

August 28, 2019

Last Update Submitted That Met QC Criteria

August 26, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20150627

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bronchiectasis

Clinical Trials on hMSCs

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe